MK-1084 + Cetuximab for Cancer
(KANDLELIT-014 Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores whether MK-1084, an experimental treatment, alone or with cetuximab, can shrink or eliminate certain advanced cancers in individuals with a specific gene change called the KRAS G12C mutation. Researchers aim to assess the effectiveness and safety of these treatments. The trial seeks participants with advanced solid tumors (excluding colorectal cancer) that have not responded to standard treatments and possess the KRAS G12C mutation. As a Phase 2 trial, the research focuses on evaluating the treatment's effectiveness in an initial, smaller group.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Research has shown that MK-1084, whether used alone or with cetuximab, generally has a manageable safety profile for patients with certain advanced cancers. Most patients tolerate MK-1084 on its own, though some experience usually manageable side effects. In studies, about 58% of patients taking only MK-1084 reported treatment-related side effects.
When combined with cetuximab, early data suggest that this combination remains manageable in terms of safety. However, more patients tend to experience side effects with both drugs, with 94% reporting some side effects. Despite this, the combination is still considered tolerable.
In summary, both MK-1084 alone and with cetuximab are generally safe, though side effects can occur, especially when the drugs are used together.12345Why are researchers excited about this trial's treatments?
Researchers are excited about MK-1084 and its combination with Cetuximab because they offer new approaches for treating cancer. Unlike standard treatments, which often target cancer cells broadly, MK-1084 works by targeting specific molecular pathways that are less likely to affect healthy cells. This precision could lead to fewer side effects and improve patient outcomes. Furthermore, when combined with Cetuximab, an established cancer therapy, MK-1084 may enhance the overall effectiveness by attacking cancer through multiple mechanisms. This combination approach provides a promising new avenue for tackling difficult-to-treat cancers.
What evidence suggests that MK-1084 alone or with cetuximab could be effective for advanced solid tumors with the KRAS G12C mutation?
Research shows that MK-1084 may help treat certain advanced solid tumors with the KRAS G12C mutation. In this trial, participants will receive either MK-1084 alone or in combination with cetuximab. Studies found that MK-1084 alone caused tumors to shrink in 38% of patients. When combined with cetuximab, this increased to 46%. Additionally, the combination stopped cancer growth in 92% of cases. These findings suggest that MK-1084, both alone and with cetuximab, can be effective against tumors with the KRAS G12C mutation.26789
Who Is on the Research Team?
Medical Director
Principal Investigator
Merck Sharp & Dohme LLC
Are You a Good Fit for This Trial?
This trial is for individuals with advanced solid tumors, excluding colorectal cancer, that have worsened despite standard treatments. Participants must have a specific genetic change called the KRAS G12C mutation in their tumor.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive MK-1084 alone or in combination with Cetuximab until criteria for discontinuation are met
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Cetuximab
- MK-1084
Find a Clinic Near You
Who Is Running the Clinical Trial?
Merck Sharp & Dohme LLC
Lead Sponsor
Chirfi Guindo
Merck Sharp & Dohme LLC
Chief Marketing Officer since 2022
Degree in Engineering from Ecole Centrale de Paris, MBA from New York University Stern School of Business
Robert M. Davis
Merck Sharp & Dohme LLC
Chief Executive Officer since 2021
JD from Northwestern University Pritzker School of Law, MBA from Northwestern University Kellogg Graduate School of Management, Bachelor's in Finance from Miami University